Lungs News and Research

RSS

Cardiovascular disease: The leading cause of death in UK

Cardiovascular disease is the leading cause of death in the UK, accounting for a third of all fatalities through illnesses such as stroke and heart disease.

4 Jun 2013

Debiopharm evaluates Debio 1143 in combination with Carboplatin and Paclitaxel in NSCLC patients

Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.

4 Jun 2013

Cancer immunotherapy shows promise in treating patients with metastatic tumors

Cancer immunotherapy is showing promise in treating patients with a variety of advanced, metastatic tumors, as evidenced by two newly unveiled studies from Yale Cancer Center.

4 Jun 2013

New tool enables doctors to monitor infections, inflammation and scarring in lungs

Intensive care patients who are on breathing support could be helped by a new tool to enable doctors to see inside their lungs to check for and monitor infections, inflammation and scarring.

4 Jun 2013

Three health education leaders to be honored as 2013 Champions of Health Professions Diversity

Three inspiring leaders in health education will be honored by The California Wellness Foundation as the 2013 Champions of Health Professions Diversity for their successful efforts to improve the health and wellness of California's most underserved communities.

4 Jun 2013

Study: Mutations in gene NTRK1 cause a subset of lung cancers

To the list of oncogenic drivers of lung cancer that includes ALK, EGFR, ROS1 and RET, results of a University of Colorado Cancer Center study presented at ASCO 2013 show that mutations in the gene NTRK1 cause a subset of lung cancers.

4 Jun 2013

Study provides important details for recently identified target in lung adenocarcinoma

In results presented at ASCO 2013, a University of Colorado Cancer Center study provides important details for a recently identified driver and target in lung adenocarcinoma: rearrangement of the gene RET.

4 Jun 2013

Data from Nivolumab phase I study in patients with kidney cancer to be presented at ASCO 2013

Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center will present a poster on a phase I clinical trial of Nivolumab, a PD-1 receptor blocking antibody, being used in combination with other drugs in patients with metastatic renal cell carcinoma at the ASCO Annual Meeting on June 3, 2013.

4 Jun 2013

ImmunoGen presents first clinical data of IMGN853 at ASCO annual meeting

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload ADC technology, today announced the presentation of the first clinical data with the Company's IMGN853 product candidate.

3 Jun 2013

New drug shows promising results with manageable side effects for treating melanoma

Researchers from UCLA's Jonsson Comprehensive Cancer Center report that a new drug in preliminary tests has shown promising results with very manageable side effects for treating patients with melanoma, the deadliest form of skin cancer.

3 Jun 2013

Lung cancer patients are likely to fare better if treated with targeted therapy than with chemotherapy

Thousands of patients with an advanced form of lung cancer that carries a specific dysfunctional gene are likely to fare better if treated with a targeted therapy than with traditional chemotherapy, report Dana-Farber Cancer Institute researchers and a team of international collaborators.

3 Jun 2013

Activ8rlives 2.0 goes live with new self monitoring capabilities for health and wellness

Activ8rlives’ website version 2.0 has now gone live after several months of preparation and testing. Activ8rlives focuses its online self monitoring solutions for health and wellness, which is utilized by families, groups and companies.

3 Jun 2013

Lambrolizumab shows significant antitumor activity in patients with advanced melanoma

Researchers from UCLA's Jonsson Comprehensive Cancer Center led by Dr. Antoni Ribas, professor of medicine in the division of hematology-oncology, report preliminary results showing significant antitumor activity with very manageable side effects from a new drug being tested in patients with advanced melanoma, the deadliest form of skin cancer.

3 Jun 2013

Study finds HER2 irregularities in 14 different advanced solid tumors

The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes's expression - among them mutations, amplifications, substitutions, and translocations - have been found in 14 different advanced solid tumors.

3 Jun 2013

Sorafenib stops tumor growth, provides effective treatment for thyroid cancer patients

The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial, which will be presented today by a researcher from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania in a plenary session during the American Society of Clinical Oncology's annual meeting.

3 Jun 2013

LUNGevity Foundation to join with WSA to empower, educate women affected by lung cancer

LUNGevity Foundation, the nation's largest lung cancer-focused nonprofit, is proud to join together with The Women Survivors Alliance in an effort to empower, educate and connect women who have been touched by cancer and represent those who have been impacted by lung cancer.

3 Jun 2013

Twitter: A popular source for receiving and sharing new information about vaccines

Twitter is a popular source for receiving and sharing new information about vaccines, and also a basically reliable one, according to a study published in the June issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC).

1 Jun 2013

Nearly 2/3 of solid tumors carry at least one mutation that may be targeted by existing compound

Nearly two-thirds of solid tumors carry at least one mutation that may be targeted, or medicated, by an existing compound, according to new findings from researchers Fox Chase Cancer Center that will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology on June 3.

1 Jun 2013

RBC transfusion during cardiac surgery can increase risk of postoperative infection

The risk of postoperative infection appears to increase when patients receive red blood cell (RBC) transfusion during or after cardiac surgery, and greater attention to practices that limit red blood cell use could potentially reduce the occurrence of major postoperative infections, according to a study published in the June 2013 issue of The Annals of Thoracic Surgery.

1 Jun 2013

New therapy for lung cancer produces manageable side effects

A promising new therapy for the most common form of lung cancer appears to produce largely manageable side effects, and an ongoing clinical trial is determining whether the compound treats tumors more effectively than what's on the market, according research that scientists at Fox Chase Cancer Center will present at the 49th Annual Meeting of the American Society of Clinical Oncology on Saturday, June 1.

1 Jun 2013

Lungs News and Research

Cardiovascular disease: The leading cause of death in UK

Debiopharm evaluates Debio 1143 in combination with Carboplatin and Paclitaxel in NSCLC patients

Cancer immunotherapy shows promise in treating patients with metastatic tumors

New tool enables doctors to monitor infections, inflammation and scarring in lungs

Three health education leaders to be honored as 2013 Champions of Health Professions Diversity

Study: Mutations in gene NTRK1 cause a subset of lung cancers

Study provides important details for recently identified target in lung adenocarcinoma

Data from Nivolumab phase I study in patients with kidney cancer to be presented at ASCO 2013

ImmunoGen presents first clinical data of IMGN853 at ASCO annual meeting

New drug shows promising results with manageable side effects for treating melanoma

Lung cancer patients are likely to fare better if treated with targeted therapy than with chemotherapy

Activ8rlives 2.0 goes live with new self monitoring capabilities for health and wellness

Lambrolizumab shows significant antitumor activity in patients with advanced melanoma

Study finds HER2 irregularities in 14 different advanced solid tumors

Sorafenib stops tumor growth, provides effective treatment for thyroid cancer patients

LUNGevity Foundation to join with WSA to empower, educate women affected by lung cancer

Twitter: A popular source for receiving and sharing new information about vaccines

Nearly 2/3 of solid tumors carry at least one mutation that may be targeted by existing compound

RBC transfusion during cardiac surgery can increase risk of postoperative infection

New therapy for lung cancer produces manageable side effects

The ultimate guide to lung research tools and protocols eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News